Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) insider Harlan S. Robins sold 1,698 shares of the firm's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $9.00, for a total value of $15,282.00. Following the completion of the transaction, the insider now directly owns 1,279,524 shares in the company, valued at approximately $11,515,716. This represents a 0.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Adaptive Biotechnologies Stock Performance
ADPT traded down $0.55 during trading on Friday, reaching $7.67. 1,563,957 shares of the company traded hands, compared to its average volume of 1,472,425. The company has a market cap of $1.14 billion, a P/E ratio of -7.04 and a beta of 1.53. Adaptive Biotechnologies Co. has a 12-month low of $2.28 and a 12-month high of $9.01. The firm has a fifty day simple moving average of $7.89 and a 200 day simple moving average of $6.38.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same quarter in the previous year, the business earned ($0.30) earnings per share. As a group, sell-side analysts expect that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Adaptive Biotechnologies
Several large investors have recently made changes to their positions in ADPT. California State Teachers Retirement System grew its holdings in Adaptive Biotechnologies by 1,060.5% during the 4th quarter. California State Teachers Retirement System now owns 97,388 shares of the company's stock valued at $584,000 after buying an additional 88,996 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter valued at $711,000. Voloridge Investment Management LLC bought a new stake in Adaptive Biotechnologies in the fourth quarter worth $174,000. Soleus Capital Management L.P. raised its stake in Adaptive Biotechnologies by 168.1% during the fourth quarter. Soleus Capital Management L.P. now owns 2,983,142 shares of the company's stock valued at $17,884,000 after purchasing an additional 1,870,393 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its position in Adaptive Biotechnologies by 265.3% during the fourth quarter. Squarepoint Ops LLC now owns 44,401 shares of the company's stock valued at $266,000 after purchasing an additional 32,247 shares during the last quarter. 99.17% of the stock is owned by institutional investors.
Analysts Set New Price Targets
ADPT has been the topic of several recent research reports. Piper Sandler reaffirmed an "overweight" rating and issued a $11.00 price objective (up previously from $7.00) on shares of Adaptive Biotechnologies in a research note on Thursday, February 20th. BTIG Research lifted their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. The Goldman Sachs Group raised shares of Adaptive Biotechnologies from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $8.00 to $9.00 in a research note on Friday, March 21st. Finally, Scotiabank lifted their target price on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $9.40.
View Our Latest Stock Report on Adaptive Biotechnologies
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Further Reading
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
